A Cohort Study on Obese Patients' Multidisciplinary Integrated Health Management (ODHM)

To explore influencing factors of diabetes remission and recovery of other complications after bariatric surgery. We design a multicenter study including respective cohort and prorespective cohort of obese patients treated with bariatric surgery or non-bariatric surgery，and collect clinical parameters and laboratory indicators.

Study Overview

• Status: Completed
• Conditions: Obesity; Bariatric Surgery; Diabete Type 2
• Intervention / Treatment: Procedure: Bariatric surgery; Other: Non-surgical threapy

• Study Type: Observational
• Enrollment (Actual): 1500

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • China-Japan Friendship Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Obese patients treated with bariatric surgery or non-bariatric surgery(diet, exercise and weight loss drugs)

Description

Inclusion Criteria:

1. Age range from 12 to 75 years,
2. BMI (Body Mass Index) ≥ 25.0 kg/m2,

Exclusion Criteria:

1. Type 1 diabetes,
2. Severe liver or kidney disease (eGFR < 30 ml/min), malignant tumors, endocrine disorders such as thyroid or Cushing's syndrome, acute coronary syndrome, uncontrolled heart failure, pregnancy or lactation, pancreatitis,
3. Contraindications to other surgeries or medications.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Non-surgical group	Other: Non-surgical threapy; Diet management，exercise，metformin，GLP-1RA and other drugs which can lose weight.
Surgical group	Procedure: Bariatric surgery; Laparoscopic sleeve gastrectomy or laparoscopic gastric bypass based on β-cell function; Other: Non-surgical threapy; Diet management，exercise，metformin，GLP-1RA and other drugs which can lose weight.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Total weight loss	1st, 3rd, 6th and 12th month after intervention, respectively.

Secondary Outcome Measures

Outcome Measure	Time Frame
Serum creatinine	1st, 3rd, 6th and 12th month after intervention, respectively.
Fasting blood glucose	1st, 3rd, 6th and 12th month after intervention, respectively.
Average blood glucose from continuous glucose monitoring	1st, 3rd, 6th and 12th month after intervention, respectively.
Postprandial 2-hour blood glucose	1st, 3rd, 6th and 12th month after intervention, respectively.
HbA1c	1st, 3rd, 6th and 12th month after intervention, respectively.
Waist circumference and hip circumference	1st, 3rd, 6th and 12th month after intervention, respectively.
Medication status	1st, 3rd, 6th and 12th month after intervention, respectively.
Quality of life score	1st, 3rd, 6th and 12th month after intervention, respectively.
AHI	1st, 3rd, 6th and 12th month after intervention, respectively.
GERDQ Score	1st, 3rd, 6th and 12th month after intervention, respectively.
Urinary microalbumin	1st, 3rd, 6th and 12th month after intervention, respectively.
TC	1st, 3rd, 6th and 12th month after intervention, respectively.
TG	1st, 3rd, 6th and 12th month after intervention, respectively.

Collaborators and Investigators

• Sponsor: China-Japan Friendship Hospital
• Investigators: Principal Investigator: Hua Meng, China-Japan Friendship Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2017
• Primary Completion (Actual): July 30, 2025
• Study Completion (Actual): July 30, 2025

Study Registration Dates

• First Submitted: May 16, 2024
• First Submitted That Met QC Criteria: February 28, 2026
• First Posted (Actual): March 5, 2026

Study Record Updates

• Last Update Posted (Actual): March 5, 2026
• Last Update Submitted That Met QC Criteria: February 28, 2026
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Diabetes Mellitus; Overweight; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Obesity; Diabetes Mellitus, Type 2; Therapeutics; Surgical Procedures, Operative; Bariatrics; Obesity Management; Bariatric Surgery
• Other Study ID Numbers: ODHM

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No